3,4-(methylenedioxy)phenyl 3-pyridyl ketone | 89667-28-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: 3,4-(methylenedioxy)phenyl 3-pyridyl ketone
• 英文别名: (2H-1,3-Benzodioxol-5-yl)(pyridin-3-yl)methanone；1,3-benzodioxol-5-yl(pyridin-3-yl)methanone
• CAS: 89667-28-7
• 化学式: C₁₃H₉NO₃
• 分子量: 227.219
• InChiKey: VLZRHMMWQIEKDF-UHFFFAOYSA-N

物化性质

• 熔点：
  112-113 °C
• 沸点：
  405.2±45.0 °C(Predicted)
• 密度：
  1.321±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  48.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3,4-(methylenedioxy)phenyl 3-pyridyl ketone 生成 7-Benzo[1,3]dioxol-5-yl-7-pyridin-3-yl-hept-6-enoic acid
  参考文献：
  名称：

  SHINJI, TERAO;KOBEI, NISHIKAWA

  摘要：

  DOI：
• 作为产物：
  描述：

  1,3-Benzodioxol-5-yl(pyridin-3-yl)methanol 生成 3,4-(methylenedioxy)phenyl 3-pyridyl ketone
  参考文献：
  名称：

  TEHRAO, SINDZI;NISIKAVA, KOXEHJ

  摘要：

  DOI：

文献信息

• 7-phenyl-7-(3-pyridyl)-6-heptenoic acid or derivatives thereof which
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US04727078A1

  公开（公告）日：1988-02-23

  Novel compound of the formula: ##STR1## wherein R.sup.1 is pyridyl group, R.sup.2 is a phenyl group, a thienyl group, a furyl group, a naphthyl group, a benzothienyl group or pyridyl group, which may optionally have a lower alkoxy group, a lower alkyl group, a halogen atom, trifluoromethyl group, a lower alkenyl group or methylenedioxy group, R.sup.3 is hydrogen atom or a lower alkyl group, and n is an integer of 0 to 6, Y is sulphur atom, methylene group or a group of the formula: ##STR2## wherein R.sup.4 is hydrogen atom or acetyl group, and m is 0 or 1, and their pharmaceutically acceptable salts have an inhibitory action on bio-synthesis of thromboxane A.sub.2 (TXA.sub.2) and an effect of accelerating the productivility of prostaglandin I.sub.2 (PGI.sub.2), and can be used for mammals to the prophylaxis or therapy of thrombosis caused by platelet aggregation or ischemic diseases caused by vasospasms in cardiac, cerebral and peripheral circulatory system (e.g. cardiac infarction, apoplexy, infarct of blood vessels in kidney, lung and other organs, pectic ulcer, etc.).

  化合物的新型配方：##STR1## 其中，R.sup.1是吡啶基，R.sup.2是苯基，噻吩基，呋喃基，萘基，苯并噻吩基或吡啶基，可选地带有较低的烷氧基，较低的烷基，卤素原子，三氟甲基基团，较低的烯基或亚甲二氧基基团，R.sup.3是氢原子或较低的烷基，n是0到6的整数，Y是硫原子，亚甲基基团或公式的基团：##STR2## 其中，R.sup.4是氢原子或乙酰基，m是0或1，它们的药学上可接受的盐具有抑制血栓素A.sub.2（TXA.sub.2）的生物合成作用和加速前列腺素I.sub.2（PGI.sub.2）的产生能力，可用于哺乳动物的预防或治疗由血小板聚集引起的血栓形成或由心脏，脑和周围循环系统的血管痉挛引起的缺血性疾病（例如心肌梗塞，中风，肾脏，肺和其他器官的血管梗塞，消化性溃疡等）。
• Certain pyridyl alkenoic acid derivatives which inhibit the action of
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US04760068A1

  公开（公告）日：1988-07-26

  Novel compound of the formula: ##STR1## wherein R.sup.1 is pyridyl group, R.sup.2 is a phenyl group, a thienyl group, a furyl group, a naphthyl group, a benzothienyl group or pyridyl group, which may optionally have a lower alkoxy group, a lower alkyl group, a halogen atom, trifluoromethyl group, a lower alkenyl group or methylenedioxy group, R.sup.3 is hydrogen atom or a lower alkyl group, and n is an integer of 0 to 6, Y is sulphur atom, methylene group or a group of the formula: ##STR2## wherein R.sup.4 is hydrogen atom or acetyl group, and m is 0 or 1, and their pharmaceutically acceptable salts having an inhibitory action on bio-synthesis of thromboxane A.sub.2 (TXA.sub.2) and an effect of accelerating the productivility of prostaglandin I.sub.2 (PGI.sub.2), and can be used for mammals to the prophylaxis or therapy of thrombosis caused by platelet aggregation or ischemic diseases caused by vasospasms in cardiac, cerebral and peripheral circulatory system (e.g. cardiac infarction, apoplexy, infarct of blood vessels in kidney, lung and other organs, pectic ulcer, etc.).

  化合物的结构式为：##STR1## 其中R.sup.1是吡啶基，R.sup.2是苯基、噻吩基、呋喃基、萘基、苯并噻吩基或吡啶基，可以选择性地具有较低的烷氧基、较低的烷基、卤素原子、三氟甲基基团、较低的烯基或亚甲氧基基团，R.sup.3是氢原子或较低的烷基，n为0到6的整数，Y是硫原子、亚甲基基团或式子：##STR2## 其中R.sup.4是氢原子或乙酰基团，m为0或1，以及其药学上可接受的盐，具有抑制血栓素A.sub.2（TXA.sub.2）的生物合成和加速前列腺素I.sub.2（PGI.sub.2）的产生的作用，并可用于哺乳动物的预防或治疗由血小板聚集引起的血栓形成或由心脏、脑和周围循环系统中的血管痉挛引起的缺血性疾病（例如心肌梗塞、中风、肾脏、肺和其他器官的血管梗塞、消化性溃疡等）。
• Process for producing substituted vinyl pyridines
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP0337640A1

  公开（公告）日：1989-10-18

  An improved process for producing a substituted vinyl pyridine compound of the general formula: wherein R¹ is pyridyl group; R² is an optionally substituted aromatic or heterocyclic group; R³ is a lower alkyl group, hydroxymethyl group, nitroxymethyl group, a nitrogen containing 5 membered ring-methyl group, an acetal-methyl group, a trialkylsilyloxymethyl group, an alkyl- or aryl­sulfonyloxymethyl group, an alkyl- or aryl-sulfonylamino­carbonyloxymethyl group, an acyloxymethyl group, an alkoxycarbonyloxymethyl group, a halogenomethyl group, an alkoxymethyl group, an aryl-oxymethyl group, cyano group, an optionally substituted carbamoyl group, an optionally substituted carbamoyloxymethyl group, an optionally substituted thiocarbamoyloxymethyl group, carboxyl group or an alkoxycarbonyl group; and n is an integer of 1 to 22, which comprises reacting a compound of the general formula: wherein R¹ and R² are as defined above, with a compound of the general formula: (C₆H₅)₃P⁺-CH₂CH₂R³·X⁻ wherein R³ is as defined above and X is a halogen atom, in a tertiary alcohol in the presence of a metallic hydride or a tertiary alkoxide of an alkali metal.

  一种生产通式为取代乙烯基吡啶化合物的改进工艺： 其中R¹是吡啶基；R²是任选取代的芳香族或杂环基团；R³是低级烷基、羟甲基、硝基、含氮五元环甲基、缩醛甲基、三烷基硅氧基甲基、烷基或芳基磺酰氧基甲基、烷基或芳基磺酰氨基羰基氧基甲基、酰氧基甲基、卤代甲基、烷氧基甲基、芳基氧基甲基、氰基、任选取代的氨基甲酰基、任选取代的氨基甲酰氧基甲基、任选取代的硫代氨基甲酰氧基甲基、羧基或烷氧基羰基；和 n 是 1 至 22 的整数，其中包括使通式如下的化合物发生反应： 其中 R¹ 和 R² 如上定义，与通式化合物反应： (c₆h₅)₃p⁺-ch₂ch₂r³-x- 其中 R³ 如上定义，X 为卤素原子。
• Thromboxane synthetase inhibitors (TXSI). Design, synthesis, and evaluation of a novel series of .omega.-pyridylalkenoic acids
  作者：Kaneyoshi Kato、Shigenori Ohkawa、Shinji Terao、Zenichi Terashita、Kohei Nishikawa

  DOI：10.1021/jm00381a005

  日期：1985.3

  A novel series of omega-pyridylalkenoic acids has been prepared by applying the Wittig reaction. Modifications were made in the omega-aryl moiety, the alkylene chain length, the alpha-methylene group adjacent to the carbonyl group, and the carboxyl group of the molecule. The compounds were tested as inhibitors of thromboxane synthetase in an in vitro assay and in ex vivo experiments with the rat. Most members of this new class of thromboxane synthetase inhibitors (TXSI) showed good activity in both assay systems. (E)-7-Phenyl-7-(3-pyridyl)-6-heptenoic acid (9c; CV-4151) was one of the most potent compounds in in vitro enzyme inhibition (IC50 = 2.6 X 10(-8) M) and, when orally administered, the most potent and long acting in the inhibition of blood thromboxane A2 production in the rat. New conceptual models I-III for the enzyme-substrate (prostaglandin H2, PGH2) and the enzyme-TXSI interactions are proposed for understanding the molecular design and structure-activity relations.
• TEHRAO, SINDZI;NISIKAVA, KOXEHJ
  作者：TEHRAO, SINDZI、NISIKAVA, KOXEHJ

  DOI：——

  日期：——